|
|
|
European Biopharmaceutical Review
|
The discovery of penicillin by Alexander Fleming in 1928 revolutionised medicine. This antibiotic soon became one of the most widely used in treating common bacterial infections, as well as pneumonia, tuberculosis, syphilis, and more (1). However, the Nobel Prize winner also predicted how an irresponsible use of penicillin could lead to the development of resistant bacteria, resulting in losing the antibiotic efficacy and death caused by a lack of alternative treatments. His concern has become a real-life scenario, affecting the medical sector and animal husbandry on a global scale.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™
San Francisco, Calif. – February 16, 2022 – Unlearn®, developer
of the Twintelligent RCT™, today announced that the company has entered
into a multi-year collaboration with Merck KGaA, Darmstadt, Germany to
accelerate late-stage clinical trials with novel trial designs that
include Digital Twins. Initially, the collaboration will focus on
advancing the regulatory approval of candidates in Merck KGaA,
Darmstadt, Germany’s immunology pipeline, with the potential to expand
into other therapeutic areas.
More info >> |
|
 |
White Papers |
 |
|
Key to Outsourcing Method Development and Validation A Pragmatic Approach
RSSL
In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >> |
|
|
